NDAINTRATRACHEALSUSPENSION
Approved
Mar 2012
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SURFAXIN (lucinactant) is a synthetic pulmonary surfactant administered via intratracheal suspension for respiratory distress syndrome in premature infants. It replaces deficient endogenous surfactant to improve lung compliance and oxygenation. The drug works by reducing surface tension in the alveoli, enabling proper gas exchange in neonates.
Peak
Product is in peak commercial lifecycle with moderate competitive pressure (30); team composition likely stable with focus on market maintenance rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SURFAXIN offers limited current job posting activity (0 linked positions), suggesting stable team structure in a mature peak-stage product. Career opportunities are likely in specialized neonatal respiratory markets, reimbursement navigation, and defending market share against competitors.
Brand ManagerMedical Science Liaison
Worked on SURFAXIN at Lee's Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.